Orchestra Biomed Holdings Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is good.Its valuation is considered fairly valued, ranking 113 out of 208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.57.In the medium term, the stock price is expected to remain stable.The company has shown average stock market performance over the past month, with weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Media Coverage
The current financial score of Orchestra Biomed Holdings Inc is 5.65, ranking 193 out of 208 in the Healthcare Equipment & Supplies industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 30.92M, representing a year-over-year increase of 12120.16%, while its net profit experienced a year-over-year increase of 137.08%.
Key Metrics
The current valuation score of Orchestra Biomed Holdings Inc is 8.38, ranking 23 out of 208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -3.84, which is -66.56% below the recent high of -1.28 and -330.72% above the recent low of -16.54.
The current earnings forecast score of Orchestra Biomed Holdings Inc is 8.00, ranking 61 out of 208 in the Healthcare Equipment & Supplies industry. The average price target is 12.00, with a high of 20.00 and a low of 10.00.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
The current price momentum score of Orchestra Biomed Holdings Inc is 5.93, ranking 168 out of 208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 4.74 and the support level at 3.94, making it suitable for range-bound swing trading.
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
The current institutional shareholding score of Orchestra Biomed Holdings Inc is 3.00, ranking 135 out of 208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 39.11%, representing a quarter-over-quarter increase of 10.06%. The largest institutional shareholder is The Vanguard, holding a total of 1.60M shares, representing 2.74% of shares outstanding, with 19.67% decrease in holdings.
The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Orchestra Biomed Holdings Inc is 2.78, ranking 146 out of 208 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.58. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
